Are you experiencing memory problems or problems carrying out day-to-day activities because of issues with your memory or thinking? Is so, you may be eligible for a study at the University of Wisconsin School of Medicine and Public Health. The Connectome Project aims to make the most detailed measurements of brain networks to date in people with mild cognitive impairment (MCI) and Alzheimer's disease.
Open Studies
People who join the Clinical Core attend a yearly visit with a study partner and undergo memory and thinking abilities evaluations. They also participate in other ADRC-affiliated studies.
A recent study by the Bendlin and Rey labs was the first to link the microbiome to Alzheimer’s disease in humans. They found that individuals with Alzheimer’s disease tend to have a reduced number and diversity of microbes in their gut. The Alzheimer's Microbiome Intervention Trial (AMBITION) will provide participants with...
The Wisconsin Alzheimer’s Disease Research Center (ADRC) and the Wisconsin Registry for Alzheimer’s Prevention (WRAP) at the University of Wisconsin-Madison are conducting a brain imaging research study to identify how Alzheimer’s disease develops. We use positron emission tomography (PET) to image amyloid plaques and neurofibrillary tangles.
A new study, ARMADA: Advancing Reliable Measurement in Alzheimer’s Disease and Cognitive Aging, will test a new set of measures on the iPad to determine whether they can detect early signs of cognitive decline.
The goal of the BRAVE study is to find out if a purified form of fish oil can stop or delay early brain changes associated with Alzheimer's disease in middle-aged, cognitively healthy Veterans at risk for this common form of dementia.
The EXERT study is looking for participants to help researchers identify the right dose of exercise for people with mild memory problems. Participants must be able to exercise at a participating local YMCA four times per week for 18 months (duration of study).
The GRADUATE I clinical study will assess how safe and effective an investigational drug is at slowing the progression of mild cognitive impairment and mild Alzheimer’s disease.
The Memory Improvement Through Nicotine Dosing (MIND) study currently being conducted by local researchers at the Wisconsin ADRC is testing whether nicotine in patch form is effective in improving memory and functioning in adults diagnosed with MCI.
The Wisconsin Alzheimer’s Disease Research Center is currently recruiting participants for a clinical research study investigating whether Elenbecestat (E2609, a BACE inhibitor) is superior to placebo in slowing disease progression (disease getting worse) in subjects age 50-85 years old with early Alzheimer’s disease.
New studies start frequently at the Wisconsin ADRC, and we're looking for men and women volunteers. In order to match interested persons with future studies, the Wisconsin ADRC has created a research database—the Wisconsin ADRC Registry—to hold the names and eligibility information of potential volunteers. When new studies become available, we will use the Wisconsin ADRC Registry to identify persons who may qualify for the new opportunity.
This unique study uses positron emission tomography (or PET for short) brain scans to visualize neuronal synapse density, amyloid plaques, and neurofibrillary tangles. We will also obtain MRI data to investigate how these factors are affecting brain health. The study examines whether AD pathology affects the quantity of synapses, and...
